Antibiotic use-ecological issues and required actions

Antibiotic Policies: Theory and Practice

Volumn , Issue , 2005, Pages 701-715

  Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41149104483     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-22852-7_35     Document Type: Chapter

References (43)

1. Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., and Fine, M. J., 2000, Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis., 31, 347-382.
2. Belongia, E. A. and Schwartz, B., 1998, Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ, 317, 668-671.
3. Bengoa, E. L., Francisco, M. M. S., and De Abajo Iglesias, J., 2002, Evolución del consumo de antibióticos en España, 1985-2000. Med. Clin. (Barc.), 118, 561-568.
4. Bruinsma, N., Hutchison, J. M., van den Bogaard, A. E., Giamarellou, H., Degener, J., and Stobberingh, E. E., 2003, Influence of population density on antibiotic resistance. J. Antimicrob. Chemother., 51, 385-390.
5. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults, 2001, J. British Thorac. Soc., 56, suppl. iv, 1-64.
6. Canet, J. and Garau, J., 2002, Importance of dose and duration of (3-lactam therapy in nasopharyngeal colonization with resistant pneumococci. J. Antimicrob. Chemother, 50, 39-43.
7. Chavers, L. S., Moser, S. A., Benjamin, W. H., Banks, S. E., Steinhauer, J. R., Smith, A. M. et al., 2003, Vancomycin-resistant enterococci: 15 years and counting. J. Hospital Infect., 53, 159-171.
8. Cunney, R. J. and Smyth, E. G, 2000, The impact of laboratory reporting practice on antibiotic utilisation. Int. J. Antimicrob. Agents, 14, 13-19.
9. Dancer, S. J., 2001, The problem with cephalosporins. J. Antimicrob. Chemother, 48, 463-478.
10. Eng, J. V, Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R. et al., 2003, Emerg. Infect. Dis., 9, 1128-1135.
11. Gould I. M., 2001, Conflicts of interest between the prescriber, the regulator and the profit maker. Clin. Microbiol. Infect., 7, suppl. 6, 1.
12. Gould, I. M., 2002a, Antibiotic policies and control of resistance. Curr. Opin. Infect. Dis., 15, 395-400.
13. Gould, I. M., 2002b, BTS guidelines on CAP. Thorax, 57, 657-658.
14. Graffunder, E. M. and Venezia, R A., 2002, Risk factors associated with nosocomial methi-cillin-resistant Staphyloccous aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother, 49, 999-1005.
15. Harbarth, S., 2000, Antibiotic policy and penicillin-G shortage. Lancet, 355, 1650.
16. Harbarth, S., 2002. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: A sociocultural perspective. Emerg. Infect. Dis., 8, 1460.
17. Howard, A. J., Magee, J. T, Fitzgerald, K. A., and Dunstan, F. D. J., 2001, Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. J. Antimicrob. Chemother, 47, 305-313.
18. Kristinnson, K. G, 1999, Modification of prescribers' behavior: The Icelandic approach. Clin. Microbiol. Infect., 5, 4S43-4S47.
19. Kümmerer, K., 2003, Significance of antibiotics in the environment. J. Antimicrob Chemother, 52, 5-7.
20. Kumarasamy, Y., Cadwgan, T, Gillanders, I. A., Jappy, B., Laing, R., and Gould, I. M., 2003, Optimizing antibiotic therapy-the Aberdeen experience. Clin. Microbiol. Infect., 9, 406-411.
21. Lelekis, M. and Gould I. M., 2001 Sequential antibiotic therapy for cost containment in the hospital setting: Why not? J. Hosp. Infect., 48, 249-257.
22. Lipsitch, M., Bergstrom, C. T, and Levin, B. R, 2000, The epidemiology of antibiotic resistance in hospitals: Pardoxes and prescriptions. PNAS, 97, 1938-1943.
23. Lipsitch, M. and Samore, M. H., 2002, Antimicrobial use and antimicrobial resistance: A population perspective. Emerg. Infect. Dis., 8, 347-354.
24. Lonks, J. R., Garau, J., and Medeiros, A. A., 2002, Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: The case of macrolides. J. Antimicrob. Chemother, 50, 87-91.
25. Kollef, M. H, 2001, Is there a role for antibiotic cycling in the intensive care unit? Crit. Care Med., 29, 135-142.
26. McCaig, L. F, Besser, R. E., and Hughes, J. M., 2003, Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000. Emerg. Infect. Dis., 9, 432-436.
27. MacKenzie, F. M., Lopez-Lozano, J. M., Beyaert, A., Camacho, M., Stuart, D., Wilson, R. et al., 2002, Modelling the temporal relationship between hospital use of macrolides, third generation cephalosporins and fluroquinolones, and the percentage of methicillin-resistant Staphylococcus aureus isolates: A time series analysis. 12th ECCMID, Milano (1), 24-27 April 2002, abstract 0231. Clin. Microbiol. Infect., 8, 32.
28. MacKenzie, A. R., Robertson, L., Jappy, B., Laing, R B. S., and Gould I. M., 2003, Audit of an antibiotic policy and microbiological investigations for treating bacteraemia in a large teaching hospital. Int. J. Antimicrob. Agents, 22, 618-621.
29. Mandell, L. A., Marrie, T. J., Grossman, R. F., Chow, A. W., and Hyland, R. H., 2000, Summary of Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can. Resp. J., 7, 371-382.
30. Oosterheert, J. J., Bonten, M. J. M., Hak, E., Schneider, M. M. E., and Hoepelman, I. M., 2003, How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J. Antimicrob. Chemother, 52, 555-563.
31. Perz, J. F., Craig, A. S., Coffey, C. S., Jorgensen, D. M., Mitchel, E., Hall, S. et al., 2002, Changes in antibiotic prescribing for children after a community-wide campaign, JAMA, 287, 3103-3109.
32. Piddock, L. J. V, 1995, Quinolone resistance and Campylobacter spp. 36, 891-898.
33. Polk, R, Johnson, C, Clarke, J., Edmond, M., and Wenzel, R., 2001, Trends in fluoroquinolone (FQ) prescribing in 35 U.S. hospitals and resistance for P. aeruginosa: A SCOPE-MMIT report (abstract). In 41st ICAAC Abstracts Addendum, December 16-19, 2001. American Society for Microbiology, 1, Washington, DC.
34. Shackley, P., Cairns, J., and Gould, I. M., 1997, Accelerated bacteriological evaluation in the management of lower respiratory tract infection in general practice. J. Antimicrob Chemother, 39, 663-666.
35. Scottish Infections Standards and Strategies (SISS) Group. 2003, Good practice guidance for antibiotic prescribing in hospital. J. R. Coll. Physicians, 33, 281-284.
36. Steinke, D. T, Seaton, R. A., Phillips, G, MacDonald T. M., and Davey, P. G, 2001, Prior trimethoprim use and trimethoprim-resistant urinary tract infection: A nested case-control study with multivariate analysis for other risk factors. J. Antimicrob. Chemother., 47, 781-787.
37. Stobberingh, E., van den Bogaard, A., London, N, Driessen, C, Top, J., and Willems, R., 1999, Enterococci with glycopeptide resistance in turkeys, turkey farmers, turkey slaughterers, and (sub) urban residents in the South of the Netherlands: Evidence for transmission of vancomycin resistance from animals to humans? Antimicrob. Agents Chemother, 43, 2215-2221.
38. Strausbaugh, L. J., Jernigan, D. B., Liedtke, L. A., and The Infectious Diseases Society of America Emerging Infections Network, 2001, National shortages of antimicrobial agents: Results of 2 survey form the Infectious Diseases Society of America Emerging Infections Network. Clin. Infect. Dis., 33, 1495-501.
39. Taylor, D J., 1999, Antimicrobial use in animals and its consequences for human health, Clin. Microbial. Infect., 5, 119-124.
40. Threkfall, E. J., Fisher, I. S. T, Berghold, C, Gerner-Smidt, Tschäpe, H., Cormican, M. et al., 2003, Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. 22, 487-491.
41. Wazana, A., 2000, Physicians and the pharmaceutical industry. 283, 373-380.
42. Wegener, H, 2003, Ending the use of antimicrobial growth promoters is making a difference. 69, 443-448.
43. WHO report, 2003, Will antibiotic misuse now stop? 1, 85.